Table 3.
The coexpression of TH components and known marker genes at Stage 30 and Stage 31
| stage | gene 1 | gene 2 | % gene 1+ cells | % gene 2+ cells | % of gene 1+ cells that are also gene 2+ | % of gene 2+ cells that are also gene 1+ |
| 30 | crx | visinin | 20.9 | 19.2 | 89.4 | 97.5 |
| 30 | visinin | crx | 17.1 | 17.3 | 95.2 | 93.8 |
| 30 | dio2 | cath5 | 1.1 | 16.3 | 85.7 | 5.8 |
| 30 | cath5 | dio2 | 13.5 | 0.6 | 4.3 | 100 |
| 30 | visinin | TRb | 16.7 | 14.6 | 60.9 | 69.6 |
| 30 | TRb | visinin | 17.6 | 16.3 | 70.3 | 75.9 |
| 31 | neurod | cath5 | 22.5 | 9.5 | 12.4 | 29.3 |
| 31 | neurod | TRb | 20.4 | 6.9 | 30.1 | 89.3 |
| 31 | otx2 | cath5 | 28.6 | 10.4 | 6 | 16.5 |
| 31 | TRb | cath5 | 8.7 | 12.3 | 10.3 | 7.2 |
| 31 | TRb | crx | 8.5 | 17.6 | 87.4 | 42.1 |
Cells were labeled in ovo with [3H]-thymidine for 1 hour, and tissue was harvested and dissociated at the indicated times. DISH for the indicated genes and autoradiography for [3H] were carried out on the dissociated cells.